{"doc_id": "33472855", "type of study": "Therapy", "title": "", "abstract": "Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019: randomised controlled trial.\nTo determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 (covid-19).\nRandomised, open label trial.\nNine hospitals in Brazil, 8 May to 17 July 2020.\nAdults with confirmed covid-19 who were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two serum biomarkers (C reactive protein, D dimer, lactate dehydrogenase, or ferritin).\nThe data monitoring committee recommended stopping the trial early, after 129 patients had been enrolled, because of an increased number of deaths at 15 days in the tocilizumab group.\nTocilizumab (single intravenous infusion of 8 mg/kg) plus standard care (n=65) versus standard care alone (n=64).\nMAIN OUTCOME MEASURE : The primary outcome, clinical status measured at 15 days using a seven level ordinal scale, was analysed as a composite of death or mechanical ventilation because the assumption of odds proportionality was not met.\nA total of 129 patients were enrolled (mean age 57 (SD 14) years; 68% men) and all completed follow-up.\nAll patients in the tocilizumab group and two in the standard care group received tocilizumab.\n18 of 65 (28%) patients in the tocilizumab group and 13 of 64 (20%) in the standard care group were receiving mechanical ventilation or died at day 15 (odds ratio 1.54, 95% confidence interval 0.66 to 3.66; P=0.32).\nDeath at 15 days occurred in 11 (17%) patients in the tocilizumab group compared with 2 (3%) in the standard care group (odds ratio 6.42, 95% confidence interval 1.59 to 43.2).\nAdverse events were reported in 29 of 67 (43%) patients who received tocilizumab and 21 of 62 (34%) who did not receive tocilizumab.\nIn patients with severe or critical covid-19, tocilizumab plus standard care was not superior to standard care alone in improving clinical outcomes at 15 days, and it might increase mortality.\nTRIAL REGISTRATION : ClinicalTrials.gov NCT04403685.\n\u00a9 Author(s) (or their employer(s)) 2019. Re-use permitted under CC BY-NC.\nNo commercial re-use. See rights and permissions.\nPublished by BMJ.\n", "Evidence Map": {"Enrollment": [{"term": "severe or critical coronavirus disease", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 109}, {"term": "severe or critical coronavirus disease 2019", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 121}, {"term": "covid-19", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 30}, {"term": "supplemental oxygen", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 69}, {"term": "mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 95}, {"term": "severe or critical covid-19", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 44}], "Comparison Results": [], "Study Arm 1 Results": [], "Study Arm 2 Results": [], "Hypothesis": []}, "Sentence-level breakdown": [{"Section": "TITLE", "Text": "Effect of tocilizumab on clinical outcomes at 15 days in patients with severe or critical coronavirus disease 2019 : randomised controlled trial .", "Evidence Elements": {"Participant": [{"term": "severe or critical coronavirus disease", "negation": "affirmed", "UMLS": {}, "start": 71, "end": 109}], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 10, "end": 21}], "Outcome": [{"term": "clinical outcomes", "negation": "affirmed", "UMLS": {}, "start": 25, "end": 42}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "OBJECTIVE", "Text": "To determine whether tocilizumab improves clinical outcomes for patients with severe or critical coronavirus disease 2019 ( covid-19 ) .", "Evidence Elements": {"Participant": [{"term": "severe or critical coronavirus disease 2019", "negation": "affirmed", "UMLS": {}, "start": 78, "end": 121}], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 21, "end": 32}], "Outcome": [{"term": "clinical outcomes", "negation": "affirmed", "UMLS": {}, "start": 42, "end": 59}], "Observation": [{"term": "improves", "negation": "affirmed", "UMLS": {}, "start": 33, "end": 41}], "Count": []}, "Evidence Propositions": []}, {"Section": "DESIGN", "Text": "Randomised , open label trial .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "SETTING", "Text": "Nine hospitals in Brazil , 8 May to 17 July 2020 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "Adults with confirmed covid-19 who were receiving supplemental oxygen or mechanical ventilation and had abnormal levels of at least two serum biomarkers ( C reactive protein , D dimer , lactate dehydrogenase , or ferritin ) .", "Evidence Elements": {"Participant": [{"term": "covid-19", "negation": "affirmed", "UMLS": {}, "start": 22, "end": 30}, {"term": "supplemental oxygen", "negation": "affirmed", "UMLS": {}, "start": 50, "end": 69}, {"term": "mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 73, "end": 95}], "Intervention": [], "Outcome": [{"term": "levels of at", "negation": "affirmed", "UMLS": {}, "start": 113, "end": 125}, {"term": "two serum biomarkers", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 152}, {"term": "C reactive protein", "negation": "affirmed", "UMLS": {}, "start": 155, "end": 173}, {"term": "dimer", "negation": "affirmed", "UMLS": {}, "start": 178, "end": 183}, {"term": "lactate", "negation": "affirmed", "UMLS": {}, "start": 186, "end": 193}], "Observation": [{"term": "abnormal", "negation": "affirmed", "UMLS": {}, "start": 104, "end": 112}], "Count": []}, "Evidence Propositions": []}, {"Section": "PARTICIPANTS", "Text": "The data monitoring committee recommended stopping the trial early , after 129 patients had been enrolled , because of an increased number of deaths at 15 days in the tocilizumab group .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "number of deaths at 15 days", "negation": "affirmed", "UMLS": {}, "start": 132, "end": 159}], "Observation": [{"term": "increased", "negation": "affirmed", "UMLS": {}, "start": 122, "end": 131}], "Count": []}, "Evidence Propositions": []}, {"Section": "INTERVENTIONS", "Text": "Tocilizumab ( single intravenous infusion of 8 mg / kg ) plus standard care ( n = 65 ) versus standard care alone ( n = 64 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "Tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 11}, {"term": "plus standard care", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 75}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "MAIN OUTCOME MEASURE : The primary outcome , clinical status measured at 15 days using a seven level ordinal scale , was analysed as a composite of death or mechanical ventilation because the assumption of odds proportionality was not met .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [{"term": "clinical status", "negation": "affirmed", "UMLS": {}, "start": 45, "end": 60}, {"term": "composite of death or mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 135, "end": 179}], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "A total of 129 patients were enrolled ( mean age 57 ( SD 14 ) years ; 68 % men ) and all completed follow-up .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "All patients in the tocilizumab group and two in the standard care group received tocilizumab .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 31}, {"term": "standard care", "negation": "affirmed", "UMLS": {}, "start": 53, "end": 66}, {"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 20, "end": 31}], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "RESULTS", "Text": "18 of 65 ( 28 % ) patients in the tocilizumab group and 13 of 64 ( 20 % ) in the standard care group were receiving mechanical ventilation or died at day 15 ( odds ratio 1.54 , 95 % confidence interval 0.66 to 3.66 ; P= 0.32 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 34, "end": 45}, {"term": "standard care", "negation": "affirmed", "UMLS": {}, "start": 81, "end": 94}], "Outcome": [{"term": "mechanical ventilation", "negation": "affirmed", "UMLS": {}, "start": 116, "end": 138}, {"term": "died", "negation": "affirmed", "UMLS": {}, "start": 142, "end": 146}], "Observation": [], "Count": [{"term": "18 of 65 ( 28 % ) patients", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 26}, {"term": "13 of 64 ( 20 % )", "negation": "affirmed", "UMLS": {}, "start": 56, "end": 73}]}, "Evidence Propositions": [{"Intervention": "tocilizumab", "Observation": "", "Count": "18 of 65 ( 28 % ) patients", "Outcome": "mechanical ventilation"}, {"Intervention": "standard care", "Observation": "", "Count": "13 of 64 ( 20 % )", "Outcome": "mechanical ventilation"}, {"Intervention": "standard care", "Observation": "", "Count": "13 of 64 ( 20 % )", "Outcome": "died"}]}, {"Section": "RESULTS", "Text": "Death at 15 days occurred in 11 ( 17 % ) patients in the tocilizumab group compared with 2 ( 3 % ) in the standard care group ( odds ratio 6.42 , 95 % confidence interval 1.59 to 43.2 ) .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "affirmed", "UMLS": {}, "start": 57, "end": 68}, {"term": "standard care", "negation": "affirmed", "UMLS": {}, "start": 106, "end": 119}], "Outcome": [{"term": "Death at 15 days", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 16}], "Observation": [], "Count": [{"term": "11 ( 17 % ) patients", "negation": "affirmed", "UMLS": {}, "start": 29, "end": 49}, {"term": "2 ( 3 % )", "negation": "affirmed", "UMLS": {}, "start": 89, "end": 98}]}, "Evidence Propositions": [{"Intervention": "tocilizumab", "Observation": "", "Count": "11 ( 17 % ) patients", "Outcome": "Death at 15 days"}, {"Intervention": "standard care", "Observation": "", "Count": "2 ( 3 % )", "Outcome": "Death at 15 days"}]}, {"Section": "RESULTS", "Text": "Adverse events were reported in 29 of 67 ( 43 % ) patients who received tocilizumab and 21 of 62 ( 34 % ) who did not receive tocilizumab .", "Evidence Elements": {"Participant": [], "Intervention": [{"term": "tocilizumab", "negation": "negated", "UMLS": {}, "start": 72, "end": 83}], "Outcome": [{"term": "Adverse events", "negation": "affirmed", "UMLS": {}, "start": 0, "end": 14}], "Observation": [], "Count": [{"term": "29 of 67 ( 43 % ) patients", "negation": "affirmed", "UMLS": {}, "start": 32, "end": 58}, {"term": "21 of 62 ( 34 %", "negation": "affirmed", "UMLS": {}, "start": 88, "end": 103}]}, "Evidence Propositions": [{"Intervention": "tocilizumab", "Observation": "", "Count": "29 of 67 ( 43 % ) patients", "Outcome": "Adverse events"}]}, {"Section": "CONCLUSIONS", "Text": "In patients with severe or critical covid-19 , tocilizumab plus standard care was not superior to standard care alone in improving clinical outcomes at 15 days , and it might increase mortality .", "Evidence Elements": {"Participant": [{"term": "severe or critical covid-19", "negation": "affirmed", "UMLS": {}, "start": 17, "end": 44}], "Intervention": [{"term": "tocilizumab plus standard care", "negation": "affirmed", "UMLS": {}, "start": 47, "end": 77}, {"term": "standard care alone", "negation": "negated", "UMLS": {}, "start": 98, "end": 117}], "Outcome": [{"term": "clinical outcomes", "negation": "negated", "UMLS": {}, "start": 131, "end": 148}], "Observation": [{"term": "superior", "negation": "negated", "UMLS": {}, "start": 86, "end": 94}, {"term": "improving", "negation": "negated", "UMLS": {}, "start": 121, "end": 130}], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "TRIAL REGISTRATION : ClinicalTrials.gov NCT04403685 .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "\u00a9 Author (s ) ( or their employer (s ) ) 2019 . Re-use permitted under CC BY-NC .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "No commercial re-use . See rights and permissions .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}, {"Section": "UNKNOWN", "Text": "Published by BMJ .", "Evidence Elements": {"Participant": [], "Intervention": [], "Outcome": [], "Observation": [], "Count": []}, "Evidence Propositions": []}]}